SeaSpine reported 1Q19 revenue of USD $36.2MM, +9% vs. 1Q18.
- Increased 2019 guidance by $2MM (1.5%) on the low end, bringing updated guidance range to $154MM to $156MM (+7.5 to 9% vs. 2018)
- Spine revenue growth driven by new products, particularly the Shoreline and Mariner systems along with NanoMetalene products
- Orthobiologics revenue growth driven by new products such as OsteoStrand Plus
- Ex-U.S. revenue grew 14.5%, primarily on the strength of Europe
Segment sales and growth on an as-reported basis:
1Q19 | 1Q18 | $ Chg | % Chg | |
Spine | $17.1 | $15.2 | $2.0 | 13.0% |
Orthobiologics | $19.0 | $18.0 | $1.0 | 5.6% |
Total | $36.2 | $33.2 | $3.0 | 9.0% |
Revenue by geographic region:
Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
US | $32.0 | $29.5 | $2.4 | 8.3% |
Ex-US | $4.2 | $3.6 | $0.5 | 14.5% |
Total | $36.2 | $33.2 | $3.0 | 9.0% |
Net earnings:
1Q19 | Amount ($MM) | % of Sales |
Sales | $36.2 | |
Cost of Sales | -$13.6 | 37.6% |
Other | -$0.74 | 2.0% |
R & D | -$3.5 | 9.7% |
Selling and Admin | -$27.3 | 75.5% |
Net Earnings | -$9.0 | -24.9% |
Sources: SeaSpine
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
SeaSpine reported 1Q19 revenue of USD $36.2MM, +9% vs. 1Q18.
Increased 2019 guidance by $2MM (1.5%) on the low end, bringing updated guidance range to $154MM to $156MM (+7.5 to 9% vs. 2018)
Spine revenue growth driven by new products, particularly the Shoreline and Mariner systems along with NanoMetalene products
Orthobiologics...
SeaSpine reported 1Q19 revenue of USD $36.2MM, +9% vs. 1Q18.
- Increased 2019 guidance by $2MM (1.5%) on the low end, bringing updated guidance range to $154MM to $156MM (+7.5 to 9% vs. 2018)
- Spine revenue growth driven by new products, particularly the Shoreline and Mariner systems along with NanoMetalene products
- Orthobiologics revenue growth driven by new products such as OsteoStrand Plus
- Ex-U.S. revenue grew 14.5%, primarily on the strength of Europe
Segment sales and growth on an as-reported basis:
1Q19 | 1Q18 | $ Chg | % Chg | |
Spine | $17.1 | $15.2 | $2.0 | 13.0% |
Orthobiologics | $19.0 | $18.0 | $1.0 | 5.6% |
Total | $36.2 | $33.2 | $3.0 | 9.0% |
Revenue by geographic region:
Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
US | $32.0 | $29.5 | $2.4 | 8.3% |
Ex-US | $4.2 | $3.6 | $0.5 | 14.5% |
Total | $36.2 | $33.2 | $3.0 | 9.0% |
Net earnings:
1Q19 | Amount ($MM) | % of Sales |
Sales | $36.2 | |
Cost of Sales | -$13.6 | 37.6% |
Other | -$0.74 | 2.0% |
R & D | -$3.5 | 9.7% |
Selling and Admin | -$27.3 | 75.5% |
Net Earnings | -$9.0 | -24.9% |
Sources: SeaSpine
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.